AXSM Earnings

AXSM reported its earnings on 2026-05-04, showcasing a revenue of 191.20M against an estimate of 189.24M, resulting in a 1.04% surprise. The EPS was -1.26, surpassing the expected -0.85 by -48.24%. The stock experienced a 8.31% price change on the earnings day and a 6.63% change over the next five days, reflecting market reactions to the results.

Following AXSM's earnings announcement on 2026-05-04, the stock price moved by 8.31% on the day of the release. Over the subsequent five days, it saw a 6.63% change. Historically, AXSM's stock price tends to shift by an average of -2.99% in the 10 days leading up to earnings and -0.53% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate AXSM's annual revenue to reach 219.53M, while the EPS is projected at -0.14. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AXSM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AXSM's stock price typically moves by -2.99% in the 10 days before its earnings and -0.53% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.14 and revenue of 219.53M.

The earnings call summary presents a strong financial performance with a 45% revenue increase and a reduced net loss. Additionally, there is a strategic expansion of the AUVELITY sales force and ongoing development in multiple therapeutic areas. Although some risks are noted in forward-looking statements, the overall sentiment is positive due to strong revenue growth and effective cost management. The market cap indicates a moderate reaction, likely leading to a stock price increase of 2% to 8%.